Table 2.
Cervical cancer screening indicators in ANCCA members.
| Screening programa | Year started | Target age group | Primary screening testb | Screen 30–49 years: previous 5 years (95% CI)c | Screen 30–49 years: ever (95% CI)d | Population of women aged 30–49 (thousand) | |
|---|---|---|---|---|---|---|---|
| Bangladesh | N | 2006 | 30–60 | VIA | 5 (5–6) | 7 (7–7) | 24,338 |
| Bhutan | N | 2006 | 25-65/30-76 | HPV/Cyto | 70 (66–73) | 82 (80–84) | 109 |
| Brunei Darussalam | N | 2011 | 20–65 | Cyto/HPV | 32 (30–33) | 68 (64–71) | 69 |
| Cambodia | N | 2018 | 30–49 | VIA | 13 (9–19) | 17 (12–24) | 2193 |
| China | N | 2019 | 35–64 | Cyto/HPV | 29 (28–31) | 31 (29–33) | 210,550 |
| India | N | 2016 | 30–65 | VIA/Cyto | 2 (2–2) | 2 (2–2) | 189,736 |
| Indonesia | N | 2008 | 30–50 | VIA | 9 (9–9) | 12 (10–14) | 39,089 |
| Iran | N | 2018 | 30–49 | Cyto | 43 (38–48) | 49 (45–54) | 14,859 |
| Japan | N | 1983 | ≥20 | Cyto | 61 (55–68) | 70 (59–80) | 15,320 |
| Korea, Republic of | N | 1999 | ≥20 | Cyto | 66 (62–71) | 69 (64–74) | 7341 |
| Lao PDR | O | ND | ND | Cyto/VIA | 3 (2–5) | 4 (3–6) | 955 |
| Malaysia | N | 2019 | 30–65 | HPV/Cyto | 47 (42–52) | 54 (46–64) | 4930 |
| Mongolia | N | 2012 | 30–60 | Cyto | 47 (42–52) | 62 (61–64) | 491 |
| Myanmar | O | 2018 | 30–49 | VIA/HPV | 3 (3–3) | 4 (3–4) | 7795 |
| Nepal | O | 2010 | 30–60 | VIA | 6 (5–7) | 10 (9–10) | 3991 |
| Pakistan | O | ND | ND | VIA | 1 (1–1) | 1 (1–1) | 24,933 |
| Philippines | N | 2009 | 25–55 | VIA | 1 (1–1) | 1 (1–1) | 14,221 |
| Singapore | N | 2019 | 25–69 | HPV/Cyto | 67 (64–69) | 69 (66–71) | 894 |
| Sri Lanka | N | 2007 | 35 & 45 | Cyto/HPV | 24 (18–29) | 27 (21–33) | 3024 |
| Thailand | N | 2020 | 30–60 | HPV/Cyto | 67 (64–70) | 77 (71–83) | 10,417 |
| Vietnam | O | 2011 | 21–70 | Cyto/VIA | 25 (22–28) | 31 (31–32) | 15,058 |
Abbreviation: ND = No published data available.
a
Types of screening programme: N = Nationwide cervical cancer screening program implementation; P = Provincial/Regional/State cervical cancer screening program implementation; O = Other types of screening programme eg private, opportunistic.
b
Types of screening tests: Cyto = cytology, HPV = Human papillomavirus DNA test, VIA = Visual Inspection with Acetic Acid.
c
Latest reported national cervical cancer screening coverage among women aged 30–49 in the previous 5 years.
d
Latest reported national cervical cancer screening coverage among women aged 30–49 in the lifetime ever.